{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:33:36Z","timestamp":1790181216114,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:00:00Z","timestamp":1419292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.clml.2014.12.008","type":"journal-article","created":{"date-parts":[[2014,12,26]],"date-time":"2014-12-26T19:48:21Z","timestamp":1419623301000},"page":"214-221.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I"],"prefix":"10.1016","volume":"15","author":[{"given":"Ruben A.","family":"Mesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Burn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Sandor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.12.008_bib1","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.12.008_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2014.12.008_bib3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.12.008_bib4","first-page":"1","article-title":"Clinical and laboratory features of myelofibrosis and limitations of current therapies","volume":"9","author":"Gregory","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2014.12.008_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2010.07.019","article-title":"MPN-associated myelofibrosis (MPN-MF)","volume":"35","author":"Mesa","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.12.008_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.12.008_bib7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3918.3918","article-title":"Weight loss, splenomegaly, and hypocholesterolemia in myeloproliferative neoplasms: patterns and relevance from the pre JAK2 inhibitor era (abstract)","volume":"114","author":"Mesa","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.12.008_bib8","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.12.008_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.12.008_bib10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/10428194.2012.710905","article-title":"The evolving treatment paradigm in myelofibrosis","volume":"54","author":"Mesa","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.12.008_bib11","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: JAK\/STAT pathway: mutations, inhibitors, and resistance","volume":"19","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.12.008_bib12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.12.008_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/asheducation-2011.1.208","article-title":"Genetic and epigenetic complexity in myeloproliferative neoplasms","volume":"2011","author":"Cross","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2014.12.008_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1615\/CritRevOncog.v17.i3.30","article-title":"Counteracting inflammation: a promising therapy in cachexia","volume":"17","author":"Argiles","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.clml.2014.12.008_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.clml.2014.12.008_bib16","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.12.008_bib17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3346\/jkms.2012.27.2.128","article-title":"Pathophysiological role of hormones and cytokines in cancer cachexia","volume":"27","author":"Kim","year":"2012","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.clml.2014.12.008_bib18","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1097\/01.mcg.0000155514.17715.39","article-title":"Inhibition of albumin synthesis in chronic diseases: molecular mechanisms","volume":"39","author":"Chojkier","year":"2005","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.clml.2014.12.008_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2548.2548","article-title":"Hypocholesterolemia is independently associated with decreased survival in patients with primary myelofibrosis: an analysis of lipid profiles in 558 myeloproliferative patients (abstract)","volume":"110","author":"Mesa","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.12.008_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2851.2851","article-title":"Decreased levels of total or HDL cholesterol in primary myelofibrosis are associated with shortened survival: DIPSS-Plus independent prognostic value (abstract)","volume":"120","author":"Sulai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.12.008_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.12.008_bib22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.12.008_bib23","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.12.008_bib24","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.12.008_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2014.12.008_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1054\/clnu.2001.0438","article-title":"The meaning of hypoalbuminaemia in clinical practice","volume":"20","author":"Franch-Arcas","year":"2001","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clml.2014.12.008_bib27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/bja\/85.4.599","article-title":"The role of albumin in critical illness","volume":"85","author":"Nicholson","year":"2000","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.clml.2014.12.008_bib28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.12.008_bib29","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.12.008_bib30","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","article-title":"Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis","volume":"83","author":"Fearon","year":"2006","journal-title":"Am J Clin Nutr"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014005448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014005448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:16Z","timestamp":1761870376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014005448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S2152265014005448"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.12.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}